PE20191481A1 - Analogo de insulina novedoso y su uso - Google Patents

Analogo de insulina novedoso y su uso

Info

Publication number
PE20191481A1
PE20191481A1 PE2019001804A PE2019001804A PE20191481A1 PE 20191481 A1 PE20191481 A1 PE 20191481A1 PE 2019001804 A PE2019001804 A PE 2019001804A PE 2019001804 A PE2019001804 A PE 2019001804A PE 20191481 A1 PE20191481 A1 PE 20191481A1
Authority
PE
Peru
Prior art keywords
amino acid
chain
insulin
insulin analog
albumin
Prior art date
Application number
PE2019001804A
Other languages
English (en)
Inventor
Sang Youn Hwang
Yong Ho Huh
Jin Young Kim
Sung Hee Hong
In Young Choi
Sung Youb Jung
Se Chang Kwon
Dae Jin Kim
Hyun Uk Kim
Myung Hyun Jang
Seung Su Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20191481A1 publication Critical patent/PE20191481A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Referida a un conjugado de analogo de insulina, en el que (i) un analogo de insulina que tiene un titulo de insulina reducido en comparacion con la forma natural, en el que una cadena B o una cadena A de insulina esta modificada mediante sustitucion de un aminoacido seleccionado del grupo constituido por el 8° aminoacido, el 23° aminoacido, el 24° aminoacido, y el 25° aminoacido de cadena B y el 1° aminoacido, el 2° aminoacido, y el 19° aminoacido de cadena A con alanina; esta unido a (ii) un material biocompatible seleccionado del grupo constituido por polietilenglicol, acido graso, colesterol, albumina y sus fragmentos, materiales de union a la albumina, polimeros de unidades de repeticion de la secuencia de aminoacidos particular, anticuerpos, fragmentos de anticuerpos, materiales de union a FcRn, tejido conectivo in vivo o sus derivados, nucleotidos, fibronectina, transferrina, sacaridos, y polimeros como portador capaz de prolongar la vida media in vivo del analogo de insulina. Asimismo, revela un metodo para preparar dicho conjugado
PE2019001804A 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso PE20191481A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20130020703 2013-02-26
KR20130082511 2013-07-12
KR20140006937 2014-01-20
PCT/KR2014/001593 WO2014133324A1 (ko) 2013-02-26 2014-02-26 신규한 인슐린 아날로그 및 이의 용도

Publications (1)

Publication Number Publication Date
PE20191481A1 true PE20191481A1 (es) 2019-10-18

Family

ID=51428522

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001747A PE20151409A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso
PE2019001804A PE20191481A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001747A PE20151409A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Country Status (25)

Country Link
US (2) US20160008483A1 (es)
EP (2) EP2963056B1 (es)
JP (3) JP6552968B2 (es)
KR (2) KR20140106452A (es)
CN (2) CN114989289A (es)
AU (2) AU2014221531B2 (es)
BR (1) BR112015019985A2 (es)
CA (1) CA2901873C (es)
CL (1) CL2015002330A1 (es)
DK (1) DK2963056T3 (es)
ES (2) ES2770776T3 (es)
HK (1) HK1211944A1 (es)
IL (1) IL240717B (es)
MX (1) MX366400B (es)
MY (1) MY186990A (es)
PE (2) PE20151409A1 (es)
PH (1) PH12015501814A1 (es)
PT (1) PT2963056T (es)
RU (1) RU2676729C2 (es)
SA (2) SA515360933B1 (es)
SG (2) SG11201506095TA (es)
TW (3) TWI621626B (es)
UA (1) UA119533C2 (es)
WO (1) WO2014133324A1 (es)
ZA (1) ZA201507104B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
UA119533C2 (uk) * 2013-02-26 2019-07-10 Ханмі Фарм. Ко., Лтд. Аналог інсуліну та його застосування
BR112016016578A2 (pt) * 2014-01-20 2017-10-03 Hanmi Pharm Ind Co Ltd Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
WO2016133372A2 (ko) * 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
EP3325496B1 (en) 2015-07-24 2024-02-07 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN108473548A (zh) * 2015-09-24 2018-08-31 韩美药品股份有限公司 胰岛素生产方法
TWI774694B (zh) * 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
MX2019009149A (es) * 2017-02-03 2019-10-14 Hanmi Pharm Ind Co Ltd Conjugado de material bioactivo que tiene sustentabilidad mejorada y uso del mismo.
CN110545852B (zh) 2017-02-07 2023-05-26 韩美药品株式会社 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
BR112019019823A2 (pt) * 2017-03-23 2020-04-22 Hanmi Pharm Ind Co Ltd conjugado, composição farmacêutica para prevenir ou tratar diabetes e método para tratamento de diabetes
JP7377195B2 (ja) 2017-09-29 2023-11-09 ハンミ ファーマシューティカル カンパニー リミテッド リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
SI3892628T1 (sl) 2018-06-29 2023-01-31 Akston Biosciences Corporation Ultra dolgo delujoči inzulin-fc-fuzijski proteini in postopki za uporabo
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3893934A1 (en) 2018-12-11 2021-10-20 Sanofi Insulin conjugates
CN113453703A (zh) 2018-12-21 2021-09-28 韩美药品株式会社 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
CN113365651A (zh) 2018-12-21 2021-09-07 韩美药品株式会社 包含胰岛素和胰高血糖素的药物组合物
CA3145491A1 (en) * 2019-07-31 2021-02-04 Stacey Lynn Lee Relaxin analogs and methods of using the same
WO2021126584A1 (en) * 2019-12-19 2021-06-24 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
MX2022011893A (es) 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Nuevos analogos de il-2 inmunoestimuladores.
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
HUE062716T2 (hu) 2020-04-10 2023-11-28 Akston Biosciences Corp Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások
CA3189527A1 (en) * 2020-07-24 2022-01-27 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
EP4382532A1 (en) * 2021-08-02 2024-06-12 Spiber Inc. Porous body and method for producing same
CN117769616A (zh) * 2021-08-02 2024-03-26 丝芭博株式会社 合成皮革及其制造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2009010428A1 (en) * 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
WO2010080606A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
WO2011028813A2 (en) * 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2012015692A2 (en) * 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
UA119533C2 (uk) * 2013-02-26 2019-07-10 Ханмі Фарм. Ко., Лтд. Аналог інсуліну та його застосування

Also Published As

Publication number Publication date
TW201817741A (zh) 2018-05-16
HK1211944A1 (en) 2016-06-03
RU2676729C2 (ru) 2019-01-10
KR20210109491A (ko) 2021-09-06
TW201920243A (zh) 2019-06-01
SA515360933B1 (ar) 2018-12-23
JP2019187440A (ja) 2019-10-31
PH12015501814B1 (en) 2015-12-07
JP6552968B2 (ja) 2019-07-31
IL240717B (en) 2020-05-31
CA2901873C (en) 2022-05-03
TWI755579B (zh) 2022-02-21
RU2015138536A (ru) 2017-04-03
AU2014221531A1 (en) 2015-08-27
SG10201907106VA (en) 2019-09-27
MX2015010471A (es) 2016-04-25
CN114989289A (zh) 2022-09-02
SG11201506095TA (en) 2015-09-29
NZ710882A (en) 2021-01-29
TWI708782B (zh) 2020-11-01
EP2963056B1 (en) 2019-11-13
MX366400B (es) 2019-07-08
IL240717A0 (en) 2015-10-29
EP2963056A4 (en) 2017-06-07
NZ751062A (en) 2021-04-30
AU2018267648B2 (en) 2020-04-16
TWI621626B (zh) 2018-04-21
UA119533C2 (uk) 2019-07-10
EP3616727A1 (en) 2020-03-04
ES2770776T3 (es) 2020-07-03
SA518400491B1 (ar) 2022-04-07
PT2963056T (pt) 2020-02-19
JP2021193089A (ja) 2021-12-23
ZA201507104B (en) 2019-04-24
KR20140106452A (ko) 2014-09-03
TW201520224A (zh) 2015-06-01
DK2963056T3 (da) 2020-02-17
WO2014133324A1 (ko) 2014-09-04
US20160008483A1 (en) 2016-01-14
JP2016510003A (ja) 2016-04-04
CN104995206B (zh) 2022-04-12
PE20151409A1 (es) 2015-10-07
MY186990A (en) 2021-08-26
EP3616727B1 (en) 2021-03-31
AU2014221531B2 (en) 2018-08-23
PH12015501814A1 (en) 2015-12-07
AU2018267648A1 (en) 2018-12-13
KR102413691B1 (ko) 2022-06-28
CA2901873A1 (en) 2014-09-04
CN104995206A (zh) 2015-10-21
US20180256731A1 (en) 2018-09-13
ES2868351T3 (es) 2021-10-21
BR112015019985A2 (pt) 2017-08-29
EP2963056A1 (en) 2016-01-06
CL2015002330A1 (es) 2015-12-28

Similar Documents

Publication Publication Date Title
PE20191481A1 (es) Analogo de insulina novedoso y su uso
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
CL2008001675A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
CU20200089A7 (es) Moléculas de unión contra bcma
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
PE20160950A1 (es) Biomarcadores de cancer y usos de los mismos
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
ES2530777T3 (es) Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
RS54627B1 (en) CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CL2012001540A1 (es) Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR066395A1 (es) Reovirus que tienen secuencias modificadas
NZ729417A (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
CO6741152A2 (es) Anticuerpos estables y solubles
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).